Jul 18th 2012 - Edison Investment Research today published a report on wilex entitled "Taking The Cash". In summary, the report says:
Wilex reported H1 revenues of €7.2m made of €5.9m of research payments and deferred income from the 2011 Prometheus deal plus €0.2m of diagnostic and €1.2m of research for customers. Other income, including grants, was €1m. Guidance for FY12 has increased to €16-18m; the H2 rise of €2m is mainly due to the deferred recognition of $17.5m cash received from Prometheus in July in respect of Rencarex. H1 operating costs were €13.3m, of which €6.9m was R&D. The cash use is €1.7-2m per month. (€20-24m annually). Losses in H1 reduced to €5.6m vs €10.6m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »